Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events

Journal of Medical Systems

Volumn 34, Issue 4, 2010, Pages 701-707

  Ohashi, Wataru ^a   Tanaka, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Clinical trials; Cost effective; Personalized medicines; Pharmacogenomics; SNPs; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; MIXED FUNCTION OXIDASE; VITAMIN K EPOXIDE REDUCTASE;

ADVERSE OUTCOME; ARTICLE; BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG COST; DRUG INDUSTRY; DRUG SYNTHESIS; HEALTH CARE COST; HUMAN; PHARMACOGENOMICS; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; GENETICS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG TOXICITY; HUMANS; INDIVIDUALIZED MEDICINE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; VITAMIN K EPOXIDE REDUCTASES;

EID: 77956056999     PISSN: 01485598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10916-009-9284-7     Document Type: Article

References (32)

1. W. E. Evans H. L. Mcleod 2003 Pharmacogenomics-Drug disposition, drug targets and side effects N. Engl. J. Med 348 538 549 10.1056/NEJMra020526
2. R. Weinshilboum 2003 Inheritance and drug response N. Engl. J. Med 348 529 537 10.1056/NEJMra020021
3. F. R. Ernst A. J. Grizzle 2001 Drug related morbidity and mortality: updating the cost-of-illness model J. Am. Pharm. Assoc 41 192 199
4. Z. Desta X. Zhao J. G. Shin, et al. 2002 Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin. Pharmacokinet 41 913 958 10.2165/00003088-200241120-00002
5. T. Mushiroda Y. Ohnishi S. Saito, et al. 2006 Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients J. Hum. Genet 51 249 253 10.1007/s10038-005-0354-5
6. W. Viroj 2006 Pharmacogenetic effect of cytochrome P450 2C9 polymorphisms in different populations Clin. Appl. Thromb. Hemost 12 2 219 222 10.1177/107602960601200211
7. L. R. Cardon R. M. Idury T. J. Harris, et al. 2000 Testing drug response in the presence of genetic information: sampling issues for clinical trials Pharmacogenemics 10 503 510 10.1097/00008571-200008000-00003
8. M. Fung A. Thornton K. Mybeck, et al. 2001 Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999 Drug Inf. J. 35 293 317
9. S. Huges A. Huges C. Brothers, et al. 2008 PREDICT-1(CNA106030). The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events Pharm. Stat 7 121 129 10.1002/pst.286
10. K. Sai J. Sawada H. Minami, et al. 2008 Irinotecan pharmacogenetics in Japanese cancer patients: Roles of UGTA16 and 28 Yakugaku. Zasshi 128 4 575 584 10.1248/yakushi.128.575
11. L. P. Garrison Jr. D. Lubeck D. Lalla, et al. 2007 Cost-effectiveness analysis of traszumab in the adjuvant setting for treatment of Her2-positive breast cancer Cancer 110 489 498 10.1002/cncr.22806
12. F. Brian J. Lawrence 2008 Pharmacogenetics of warfarin; regulatory, scientific, and clinical issues J. Thromb. Thrombolysis 25 45 51 10.1007/s11239-007-0104-y
13. D. L. DeMets 2002 Clinical trials in the new millennium Stat. Med 21 2779 2787 10.1002/sim.1281
14. McWilliam, A., Lutter, R., Nardinelli, C. et al., Health Care Savings from personalizing Medicine Using Genetic testing. AEI Bookings Joint Center for Regulatory Studies, Working Paper 6-23, 2006.
15. Ministry of Education, Culture, Sports, Science and Technology, Leading Project. Biobank Japan. http://www.biobankjp.org/info/IC0802.pdf. 2005.
16. D. L. Veenstra M. K. Higashi K. A. Phillips 2000 Assessing the cost-effectiveness of pharmacogenomics AAPS. PharmSci 29 3 1 11
17. Japan Pharmaceutical Manufacturers Association, Questionnaire about pharmacogenomics. https://www1.meteo-intergate.com/news/letter/119/, 2007
18. M. Hurlen M. Abdelnoor P. Smith, et al. 2002 Warfarin, aspirin, or both after myocardial infarction N. Engl. J. Med 347 13 969 974 10.1056/NEJMoa020496
19. Gallen, C., Clinical research and development. Wyeth Pharmaceuticals, Collegeville, p. 19426, 2006.
20. Japan Pharmaceutical Manufacturers Association, Proposal for extension of patent period, February, 2009 http://www.jpo.go.jp/shiryou/toushin/shingikai/ pdf/entyou-wg03-shiryou/entyou-wg-shiryou03.pdf.
21. R. R. Shah 2003 Regulatory aspects of pharmacogenetics and pharmacogenomics Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz 46 855 867 10.1007/s00103-003-0697-z
22. Yatsuda Y., Sales rank of world medicines, Utobain News release, Jul 2007. http://www.utobrain.co.jp /news-release/2007/070700/NewsRelease0707.pdf
23. The calculation is based on the data in "Commission to facilitate marketing of effective and safe medicine", MHLW, October 30, 2006. http://www.mhlw.go.jp/shingi/2007/07/dl/s0730-10a.pdf
24. Saito, H., Current Status and Issues of Drug Development Strategy in Japan. Drug Deliv. Syst. 1, 65-72, 2002.
25. Genelex. Pharmacogenetics: personalizing medicine today. In Health and DNA. Seattle, Washington U.S. 2007. http://www.healthanddna.com/professional/ pharmacogenetics.html#2c9
26. F. R. Ernst A. J. Grizzle 2001 Drug-related morbidity and mortality: updating the cost-of-illness model J. Am. Pharm. Assoc 41 192 199
27. Bureau of Labor Statistics, Consumer price index for medical care, 2002-2006.
28. M. J. Rieder 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N. Engl. J. Med 352 22 2285 2293 10.1056/NEJMoa044503
29. Genetic Information Nondiscrimination Act:GINA. http://www.house.gov/ apps/list/speech/edlabor-dem/rel050108.html
30. SNP Genotyping and Analysis Markets. Kalorama Information, 2008. http://www.infoshop-japan.com/publisher/KL.shtml
31. Cabinet Office, Government of Japan, Act on the Protection of Personal Information, May, 2003, http://www5.cao.go.jp/seikatsu/kojin/houritsu/index.html
32. Ministry of Health, Labour and Welfare, Ethical Guidelines for Human Genome and Genetic Sequencing Research, December, 2004, http://www5.cao.go.jp/ seikatsu/shingikai/kojin/20050127kojin-sanko2-3.pdf